CFTR and cystic fibrosis: As a result, compoundsviewed as unsuitable for treating certain CF genotypes and/or drugsdesigned for a specific purpose (potentiators, correctors, readthroughagents) can require independent re-evaluation to characterize effectson less well-studied CFTR abnormalities., In addition, large-scale drug analysis/theratyping programs thatlimit their protocols to chronic corrector treatment and acute additionof potentiators may fail to properlyevaluate favorable drug responses and underestimate the potentialfor clinical benefit among rare forms of the disease.